Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5387-5396

  McPhee, Fiona ^a   Sheaffer, Amy K ^a   Friborg, Jacques ^a   Hernandez, Dennis ^a   Falk, Paul ^a   Zhai, Guangzhi ^a   Levine, Steven ^a   Chaniewski, Susan ^a   Yu, Fei ^a   Barry, Diana ^a   Chen, Chaoqun ^a   Lee, Min S ^a   Mosure, Kathy ^a   Sun, Li Qiang ^a   Sinz, Michael ^a   Meanwell, Nicholas A ^a   Colonno, Richard J ^a,b   Knipe, Jay ^a   Scola, Paul ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Presidio Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASUNAPREVIR; BMS 791325; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENTIATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REPLICON; RNA VIRUS; VIRUS CHARACTERIZATION; VIRUS REPLICATION;

ANIMALS; CELL LINE; DOGS; GENOTYPE; HAPLORHINI; HEPACIVIRUS; HEPATITIS C; HUMANS; ISOQUINOLINES; MALE; MICE; RATS; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84866334428     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01186-12     Document Type: Article

References (52)

1. Bartenschlager R. 1999. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J. Viral Hepat. 6:165-181. (Pubitemid 29260100)
2. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. 1994. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J. Virol. 68:5045-5055. (Pubitemid 24226572)
3. Bartenschlager R, Lohmann V, Wilkinson T, Koch JO. 1995. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J. Virol. 69: 7519-7528.
4. Reference deleted.
5. Bronowicki J-P, et al. 2012. Asunaprevir (ASV; BMS-650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection. J. Hepatol. 56(Suppl 2):S431-S432.
6. Burns C, et al. 2004. Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases. PCT international patent application WO2004/041201.
7. Campbell JA, Good AC. 2002. Preparation of tripeptides as hepatitis C virus inhibitors. PCT international patent application WO2002/060926.
8. Chayama K, et al. 2012. Dual therapy with the NS5A inhibitor BMS- 790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders. Hepatology 55:742-748.
9. Chen S-H, et al. 2005. P1 and P1′ optimization of [3,4]-bicycloproline P2 incorporated terapeptidyl α-ketoamide based HCV protease inhibitors. Lett. Drug Design Discov. 2:118-123. (Pubitemid 40388751)
10. Chou TC. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58:621-681.
11. Clackson T, Winter G. 1989. 'Sticky feet'-directed mutagenesis and its application to swapping antibody domains. Nucleic Acids Res. 17:10163-10170. (Pubitemid 20012175)
12. Coelmont L, et al. 2006. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2=-C-methylcytidine, the active component of valopicitabine. Antimicrob. Agents Chemother. 50:3444-3446. (Pubitemid 44527521)
13. Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS. 1991. 'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res. 19:4008.
14. Drexler D, et al. 2006. Development of an on-line automated sample clean-up method and liquid chromatography-tandem mass spectrometry analysis: application in an in vitro proteolytic assay. Anal. Bioanal Chem. 384:1145-1154. (Pubitemid 43333996)
15. Fridell RA, et al. 2011. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J. Virol. 85:7312-7320.
16. Fridell RA, Qiu D, Wang C, Valera L, Gao M. 2010. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54:3641-3650.
17. Fried MW, et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
18. Gane EJ, et al. 2011. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients. J. Hepatol. 55:972-979.
19. Gao M, et al. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100.
20. Ghany MG, Strader DB, Thomas DL, Seeff LB, and American Association for the Study of Liver Diseases. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335-1374.
21. Grobler JA, et al. 2003. Identification of a key determinant of hepatitis C virus cell culture adaptation in domain II of NS3 helicase. J. Biol. Chem. 278:16741-16746. (Pubitemid 36799540)
22. Jacobson IM, et al. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416.
23. Kadow JF, et al. 2012. Discovery of BMS-791325, an allosteric NS5B replicase inhibitor for the treatment of hepatitis C, abstr. MEDI-23. 243rd American Chemical Society National Meeting and Exposition.
24. Kim AI, Saab S. 2005. Treatment of hepatitis C. Am. J. Med. 118:808-815. (Pubitemid 41097454)
25. Kuiken C, Simmonds P. 2009. Nomenclature and numbering of the hepatitis C virus. Methods Mol. Biol. 510:33-53.
26. Lamarre D, et al. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189. (Pubitemid 37442587)
27. Llinas-Brunet M, et al. 2004. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors. J. Med. Chem. 47:6584-6594. (Pubitemid 39657319)
28. Lok AS, et al. 2012. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366:216-224.
29. McHutchison JG, et al. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361:580-593.
30. McPhee F, et al. 2012. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob. Agents Chemother. 56:3670-3681.
31. McPhee F, et al. 2009. The discovery and early development of the HCV NS3 protease inhibitor BMS-605339. Global Antiviral J. 5(Suppl 1):51.
32. Merck & Co. 2011. Victrelis™ (boceprevir), package insert. Merck & Co., Whitehouse Station, NJ.
33. Miller RH, Purcell RH. 1990. Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc. Natl. Acad. Sci. U. S. A. 87:2057-2061.
34. Murakami E, et al. 2010. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J. Biol. Chem. 285:34337-34347.
35. Neurath H. 1989. The diversity of proteolytic enzymes. In Beynon RJ, Bond JS (ed) Proteolytic enzymes: a practical approach. Oxford University Press, Oxford, United Kingdom.
36. O'Boyle DR, 2nd, et al. 2005. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob. Agents Chemother. 49:1346-1353.
37. Pasquinelli C, et al. 2012. Single and multiple ascending dose studies of the NS3 protease inhibitor, asunaprevir, in subjects with or without chronic hepatitis C. Antivir. Agents Chemother. 56:1838-1844.
38. Perni RB, et al. 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50:899-909. (Pubitemid 43327793)
39. Poordad F, et al. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1195-1206.
40. Rajagopalan R, et al. 2009. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry 48:2559-2568.
41. Raney KD, Sharma SD, Moustafa IM, Cameron CE. 2010. Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J. Biol. Chem. 285:22725-22731.
42. Reagan-Shaw S, Nihal M, Ahmad N. 2008. Dose translation from animal to human studies revisited. FASEB J. 22:659-661. (Pubitemid 351348146)
43. Robertson B, et al. 1998. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch. Virol. 143:2493-2503. (Pubitemid 29022697)
44. Sarrazin C, et al. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777. (Pubitemid 46677938)
45. Scola P, et al. 2010. Discovery of BMS-650032, an NS3 protease inhibitor for the treatment of hepatitis C, abstr. MEDI-38. Scientific Abstracts for the 239th American Chemical Society National Meeting and Exposition.
46. Sheaffer AK, et al. 2011. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates. Antivir. Ther. 16:705-718.
47. Taliani M, et al. 1996. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Anal. Biochem. 240:60-67. (Pubitemid 26292923)
48. Tautz N, Kaiser A, Thiel HJ. 2000. NS3 serine protease of bovine viral diarrhea virus: characterization of active site residues, NS4A cofactor domain, and protease-cofactor interactions. Virology 273:351-363. (Pubitemid 30641377)
49. Thibeault D, et al. 2004. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J. Virol. 78:7352-7359. (Pubitemid 38915881)
50. Vertex Pharmaceuticals Inc. 2011. Incivek™ (telaprevir), package insert. Vertex Pharmaceuticals Inc., Cambridge, MA.
51. Wakita T, et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796. (Pubitemid 41021213)
52. World Health Organization. 2011. Hepatitis C key facts. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed July 2012.